Introduction
Methods
Patient selection
Grade | Criteria |
---|---|
0 | Fully active, performs at predisease level |
1 | Activity less than predisease level; able to function as acceptable pet |
2 | Severely compromised activity; ambulatory only to point of eating, |
sleeping, and consistently eliminating in acceptable areas. | |
3 | Completely disabled; must be force fed; unable to defecate or urinate |
in acceptable areas | |
4 | Dead |
Treatment
Experimental approach
Toxicity/Grade signs | Duration |
---|---|
Hospitalization | Days |
0 | 0 |
1 | 1 |
2 | 2–3 |
3 | 4–5 |
4 | ≥5 |
Neutropenia | |
0 | ≤500 neutrophils/mL |
1 | 1,500–2,500 neutrophils/mL |
2 | ≥2,500 neutrophils/mL |
3 | 500–999 neutrophils/mL |
4 | 1,000–1,499 neutrophils/mL |
Anorexia | |
0 | None |
1 | Inappetance |
2 | Anorexia ≤3 days duration |
3 | Anorexia >3 days but <5 days |
4 | Anorexia ≥5 days 10% weight loss |
Vomiting | |
0 | None |
1 | Nausea |
2 | Sporadic, self-limiting |
3 | 1–5 episodes per day, <2 days |
4 | 6–10 episodes per day, hospitalized |
Diarrhea | |
0 | None |
1 | Soft stools, responds to dietary modification |
2 | 1–4 watery stools per day, <2 days |
3 | 4–7 watery stools per day or >2 days |
4 | >7 watery stools per day or bloody,hospitalized |
Infection | |
0 | None |
1 | No medication |
2 | Required medication |
3 | Debilitating |
4 | Threatening |
Vomiting
| ||||
None | 3 episodes per day | 5 episodes per day | >5 episodes per day | >5 per day OR |
OR | OR | OR | days lasting >4 days and | |
vomiting lasting 2 days | vomiting lasting 4 days | for >4 days | life threatening | |
Diarrhea
| ||||
None | 2 more stools | 6 more stools | >6 more stools | >6 and life |
than normal | than normal | than normal | hospitalized | |
Nausea
| ||||
None | Appetite loss with | Salivating or lip | Salivation or lip | Salivation/lip |
normal eating habits | smacking for 12 hrs | smacking for 24 hrs | smacking >24 h | |
Appetite
| ||||
Normal | With treats or diet | Appetite loss for 3 days OR | Appetite loss for 5 days OR | Loss >5 days |
change, ate 100% | With treats or diet | With treats or diet | OR | |
change, ate 50% of normal | change, ate few bites | No interest, | ||
no appetite | ||||
Flatulence
| ||||
Normal | 1-2 episodes per day | 2-4 episodes per day | 4-6 episodes per day | > 6 episodes per day |
Activity
| ||||
Normal | Mild lethargy | Moderate lethargy, difficulty | Severe lethargy, only | Unable to |
with daily activities | gets up to go outside | rise on own |
Statistical analysis
Evaluation of patients
Results
Patient | Age | Sex | Tumor | Prev. treatment | Tumor stage | Outcome (weeks) |
---|---|---|---|---|---|---|
Mixed breed | 10 | FS | Metastatic Anal sac Ca (sublumbar lymph nodes) | Surgery | T0 N1 MX
| PR 40 |
Mixed breed | 12 | FS | Metastatic Anal sac Ca (sublumbar lymph nodes) | Surgery | T0 N1 MX
| CR 56 |
Mixed breed | 16 | FS | Thyroid Ca | Biopsy | T3B N0 MX
| PD |
Cocker Spaniel | 6 | MC | Liver Sarcoma | Biopsy | T2 N0 MX
| PR 30 |
Dachshund | 13 | MC | Liver Ca | Biopsy | T2 N0 MX
| CR 90+ |
Golden retriever | 14 | MC | Ruptured | Surgery | T3 N0 MX
| NED 72 |
Splenic HSA | ||||||
Labrador retriever | 12 | MC | Ruptured | Surgery | T3 N0 MX
| NED 34 |
Splenic HSA | ||||||
Golden retriever | 13 | FS | Recurring inflammatory mammary Ca | Surgery | T4 N0 MX
| CR 104+ |
Golden retriever | 10 | FS | Recurring inflammatory mammary Ca | Surgery | T4 N0 MX
| PD |
Boxer | 10 | FS | Metastatic mammary Ca (axillary lymph node) | Biopsy | T3 N1 MX
| PR 32 |
Dachshund | 13 | MC | Limb Sarcoma | Biopsy | T3 N0 MX
| CR 20 |
Labrador retriever | 11 | M | Recurring | Surgery | T2 N0 MX
| NED 30 |
Neck Sarcoma | ||||||
Mixed breed | 13 | FS | Nasal sinus AdCa | Biopsy | T3 N0 MX
| PR 24+ |
Labrador | 10 | FS | Nasal Sarcoma | Electrochemotherapy | T3 N0 MX
| PR 20+ |
Tibetan spaniel | 11 | M | Nasal carcinoma | Biopsy | T3 N0 MX
| PR 8 |
Visla | 10 | M | Nasal carcinoma | Biopsy | T2 N0 MX
| PR16+ |
Mixed breed | 10 | F | Lingual SCC | Biopsy | T2 N1A MX
| PR 16+ |
Mixed breed | 12 | FS | Lung carcinoma | Biopsy | T1 NX MX
| SD 16+ |
Mixed breed | 13 | F | Lung carcinoma | Biopsy | T1 NX MX
| PR 12 |
German Shepherd | 10 | M | Visceral histiocytosis | Biopsy | T3 N1 MX
| PD |
German shepherd | 9 | M | OSA | Biopsy | T2 NX MX
| PD |
Rottweiler | 8 | M | OSA | Biopsy | T2 NX MX
| SD 8+ |
DSH | 10 | FS | Nasal CSA | Biopsy | T2 N0 MX
| PR 100 |
DSH | 10 | FS | Recurring anaplastic mammary carcinoma | Surgery | T4 N0 MX
| NED 54+ |
Patient | Age | Sex | Tumor | Prev. treatment | Tumor stage | Outcome (weeks) |
---|---|---|---|---|---|---|
Mixed breed | 13 | FS | Metastatic | Surgery | T0 N1 MX
| PD |
Anal sac Ca (sublumbar lymph nodes) | ||||||
Poodle | 12 | MC | Thyroid Ca | Biopsy | T3B N0 MX
| PD |
Labrador | 9 | F | Liver CA | Biopsy | T2 N0 MX
| PD |
Golden retriever | 11 | MC | Ruptured | Surgery | T3 N0 MX
| NED 28 |
Splenic HSA | ||||||
German Shepherd | 10 | MC | Ruptured | Surgery | T3 N0 MX
| NED 20 |
Splenic HSA | ||||||
Boxer | 11 | FS | Inflammatory mammary Ca | Biopsy | T4 N0 MX
| CR 80+ |
Mixed breed | 13 | FS | Recurring | Surgery | T4 N0 MX
| PD |
Inflammatory mammary Ca | ||||||
Boxer | 10 | FS | Mammary Ca | Biopsy | T3C N1 MX
| PD |
Doberman | 13 | FS | Anaplastic mammary Ca (axillary lymph node) | Biopsy | T3B N1 MX
| PD |
Boxer | 11 | M C | OSA | Biopsy | T2 NX MX
| PR 40 |